These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 1758446)

  • 1. Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate.
    Aziz TZ; Peggs D; Sambrook MA; Crossman AR
    Mov Disord; 1991; 6(4):288-92. PubMed ID: 1758446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alleviation of experimental hemiparkinsonism by high-frequency stimulation of the subthalamic nucleus in primates: a comparison with L-Dopa treatment.
    Benazzouz A; Boraud T; Féger J; Burbaud P; Bioulac B; Gross C
    Mov Disord; 1996 Nov; 11(6):627-32. PubMed ID: 8914087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of the subthalamic nucleus in the origin of hemiballism and parkinsonism: new surgical perspectives.
    Guridi J; Obeso JA
    Adv Neurol; 1997; 74():235-47. PubMed ID: 9348418
    [No Abstract]   [Full Text] [Related]  

  • 4. Fifteen months' follow-up on bilateral embryonic mesencephalic grafts in two cases of severe MPTP-induced parkinsonism.
    Widner H; Tetrud J; Rehncrona S; Snow BJ; Brundin P; Björklund A; Lindvall O; Langston JW
    Adv Neurol; 1993; 60():729-33. PubMed ID: 8420218
    [No Abstract]   [Full Text] [Related]  

  • 5. Subthalamic nucleotomy alleviates parkinsonism in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed primate.
    Aziz TZ; Peggs D; Agarwal E; Sambrook MA; Crossman AR
    Br J Neurosurg; 1992; 6(6):575-82. PubMed ID: 1361741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does increased excitatory drive from the subthalamic nucleus contribute to dopaminergic neuronal death in Parkinson's disease?
    Luquin MR; Saldise L; Guillén J; Belzunegui S; San Sebastián W; Izal A; Garrido P; Vázquez M
    Exp Neurol; 2006 Oct; 201(2):407-15. PubMed ID: 16806173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The primate subthalamic nucleus. III. Changes in motor behavior and neuronal activity in the internal pallidum induced by subthalamic inactivation in the MPTP model of parkinsonism.
    Wichmann T; Bergman H; DeLong MR
    J Neurophysiol; 1994 Aug; 72(2):521-30. PubMed ID: 7983516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate.
    Brotchie JM; Mitchell IJ; Sambrook MA; Crossman AR
    Mov Disord; 1991; 6(2):133-8. PubMed ID: 1647492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
    Jenner P; Marsden CD
    J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subthalamotomy improves MPTP-induced parkinsonism in monkeys.
    Guridi J; Herrero MT; Luquin R; Guillen J; Obeso JA
    Stereotact Funct Neurosurg; 1994; 62(1-4):98-102. PubMed ID: 7631095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms.
    Bezard E; Boraud T; Bioulac B; Gross CE
    Eur J Neurosci; 1999 Jun; 11(6):2167-70. PubMed ID: 10336685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism.
    Bergman H; Wichmann T; Karmon B; DeLong MR
    J Neurophysiol; 1994 Aug; 72(2):507-20. PubMed ID: 7983515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathophysiology of parkinsonian motor abnormalities.
    Wichmann T; DeLong MR
    Adv Neurol; 1993; 60():53-61. PubMed ID: 8420185
    [No Abstract]   [Full Text] [Related]  

  • 14. [MPTP and Parkinson's disease].
    Imai H
    No To Shinkei; 1988 Nov; 40(11):1011-24. PubMed ID: 3064783
    [No Abstract]   [Full Text] [Related]  

  • 15. [A mouse model of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism: effect of norepinephrine terminal destruction].
    Nishi K; Kondo T; Narabayashi H
    No To Shinkei; 1987 Jul; 39(7):663-72. PubMed ID: 3314916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic exposure to MPTP as a primate model of progressive parkinsonism: a pilot study with a free radical scavenger.
    Blanchet PJ; Konitsiotis S; Hyland K; Arnold LA; Pettigrew KD; Chase TN
    Exp Neurol; 1998 Oct; 153(2):214-22. PubMed ID: 9784281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bilateral akinesia in drug-induced parkinsonism after a subthalamic lesion.
    Kulisevsky J; Lima de Freitas M; Barraquer-Bordas L
    Mov Disord; 1994 Jan; 9(1):111-2. PubMed ID: 8139592
    [No Abstract]   [Full Text] [Related]  

  • 18. Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates.
    Blanchet PJ; Grondin R; Bédard PJ
    Mov Disord; 1996 Jan; 11(1):91-4. PubMed ID: 8771074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical and biochemical parameters of parkinsonism induced by 1-methyl-4-phenyl-1,2,2,6-tetrahydropyridine and its methyl-phenyl and methoxy-phenyl derivatives in C57Bl/6 mice].
    Lermontova NN; Soliakov LS; Bachurin SO; Serkova TP; Petrova LN; Dranyĭ OA; Tkachenko SE; Kalashnikov VV
    Biull Eksp Biol Med; 1990 Oct; 110(10):397-9. PubMed ID: 2279092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The primate subthalamic nucleus. I. Functional properties in intact animals.
    Wichmann T; Bergman H; DeLong MR
    J Neurophysiol; 1994 Aug; 72(2):494-506. PubMed ID: 7983514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.